Skip to main
ALLO
ALLO logo

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 35%
Hold 17%
Sell 4%
Strong Sell 0%

Bulls say

Allogene Therapeutics Inc is positioned favorably due to its innovative allogeneic T-cell therapies, which demonstrate enhanced efficacy in patients with low disease burden, achieving complete response (CR) rates of 100% and 82% in specific scenarios. The anticipated regulatory developments, including a regimen selection expected in mid-2025, coupled with the promising safety profile of their lead product cema-cel, suggests potential for effective treatment options in oncological applications. Additionally, the company's collaborative revenue streams bolster their resources for ongoing research and development, underscoring a robust foundation for future growth in the competitive biotech landscape.

Bears say

Allogene Therapeutics reported a net loss of $60 million, translating to a loss of $0.28 per share, indicating significant financial strain as the company continues to operate in a non-revenue generating status. The firm faces speculative risks due to the unpredictability of future revenues and expenses, alongside potential delays in approvals or negative trial results, which could diminish investor confidence and adversely affect share price. Additionally, competitive pressures from similar products in the market could jeopardize Allogene Therapeutics' market share, further complicating its financial outlook.

ALLO has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 35% recommend Buy, 17% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 23 analysts, ALLO has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.